Modality
Peptide
MOA
CD3xCD20
Target
IL-13
Pathway
Sphingolipid
HCCT2DSLE
Development Pipeline
Preclinical
~May 2022
→ ~Aug 2023
Phase 1
~Nov 2023
→ ~Feb 2025
Phase 2
May 2025
→ Feb 2026
Phase 2Current
NCT03172842
50 pts·HCC
2025-05→2026-02·Active
50 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-141mo agoPh3 Readout· HCC
Trial Timeline
Q3Q42026
P2/3
Active
Catalysts
Ph3 Readout
2026-02-14 · 1mo ago
HCC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03172842 | Phase 2/3 | HCC | Active | 50 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| MRN-7601 | Moderna | Phase 2 | IL-13 |